

Alberto Piubello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5715783/publications.pdf>

Version: 2024-02-01

22
papers

699
citations

840119

11
h-index

713013

21
g-index

23
all docs

23
docs citations

23
times ranked

738
citing authors

#	ARTICLE	IF	CITATIONS
1	Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study. <i>International Health</i> , 2023, 15, 258-264.	0.8	1
2	High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss. <i>European Respiratory Journal</i> , 2021, 57, 2002250.	3.1	12
3	World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105822.	1.1	19
4	Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence. <i>Journal of Clinical Medicine</i> , 2020, 9, 55.	1.0	34
5	Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: Nationwide programmatic achievements. <i>Respiratory Medicine</i> , 2020, 161, 105844.	1.3	26
6	Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2020, 55, 1901467.	3.1	55
7	Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January–April 2020. <i>Emerging Infectious Diseases</i> , 2020, 26, 2709-2712.	2.0	133
8	The looming threat of bedaquiline resistance in tuberculosis. <i>European Respiratory Journal</i> , 2020, 55, 2000718.	3.1	4
9	Course of Adverse Events during Short Treatment Regimen in Patients with Rifampicin-Resistant Tuberculosis in Burundi. <i>Journal of Clinical Medicine</i> , 2020, 9, 1873.	1.0	8
10	Tuberculosis treatment: one-shot approach or cascade of regimens?. <i>Lancet Respiratory Medicine</i> , 2020, 8, e4-e5.	5.2	7
11	MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. <i>International Journal of Infectious Diseases</i> , 2020, 92, S15-S25.	1.5	126
12	Multidrug-resistant patients receiving treatment in Niger who are infected with <i>M. tuberculosis</i> Cameroon family convert faster in smear and culture than those with <i>M. tuberculosis</i> Ghana family. <i>Tuberculosis</i> , 2020, 122, 101922.	0.8	6
13	Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries. <i>EClinicalMedicine</i> , 2020, 20, 100268.	3.2	26
14	Multidrug-resistant tuberculosis. <i>Lancet</i> , 2019, 394, 299.	6.3	5
15	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. <i>European Respiratory Journal</i> , 2019, 54, 1901522.	3.1	113
16	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. <i>International Journal of Infectious Diseases</i> , 2019, 83, 72-76.	1.5	41
17	The future of drug-resistant tuberculosis treatment: learning from the past and the 2019 World Health Organization consolidated guidelines. <i>European Respiratory Journal</i> , 2019, 54, 1901272.	3.1	30
18	Should gatifloxacin be included in the model list of essential medicines?. <i>European Respiratory Journal</i> , 2018, 51, 1702329.	3.1	6

#	ARTICLE	IF	CITATIONS
19	Bedaquiline: how better to use it. European Respiratory Journal, 2017, 50, 1701670.	3.1	6
20	Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases. European Respiratory Journal, 2017, 50, 1700648.	3.1	32
21	Shifts in Mycobacterial Populations and Emerging Drug-Resistance in West and Central Africa. PLoS ONE, 2014, 9, e110393.	1.1	8
22	Adverse anti-tuberculosis drug events and their management. , 0, , 205-227.		1